Labaran Waya

Sabbin Bayanai na Alurar Ciwon daji don Tumors

Written by edita

Nouscom a yau ta sanar da ƙarfafa sabbin bayanan fassarar da aka samu daga gwaji na Mataki na 1 mai gudana yana kimanta NOUS-209. An gabatar da bayanan jiya a cikin Late Breaking zaman a 2022 American Association for Cancer Research (AACR) Taron Shekara-shekara.

NOUS-209, samfurin gubar na Nouscom, rigakafin ciwon daji ne wanda ba a kwance ba wanda ke yin niyya 209 na neoantigens da aka raba. Ana bincikar shi a cikin gwaji na asibiti na Phase 1, wanda aka gudanar tare da haɗin gwiwar anti-PD-1 mai hanawa pembrolizumab, don kula da Microsatellite Instable High (MSI-H) na ciki, launin launi da gastro-esophageal junction m ciwace-ciwacen daji.

An gabatar da bayanan asibiti na wucin gadi na haɗin gwiwa (wanda aka gabatar a taron shekara-shekara na Society for Immunotherapy of Cancer (SITC) a watan Nuwamba 2021) ya ba da haske ga alamun farkon tasirin asibiti a cikin marasa lafiya 12 MSI-H.

Sabbin bayanan fassarar da aka gabatar a AACR 2022 sun ƙara goyan bayan waɗannan binciken kuma sun nuna NOUS-209 yana da aminci, mai yawan rigakafi tare da alamun alamun ingancin asibiti. Mahimman binciken sun kasance kamar haka:

• An nuna rigakafin rigakafi ta hanyar ex-vivo IFN-ɣ ELISpot assay a cikin 67% na marasa lafiya a matakin kashi 1 (n=3), da 100% (n=7) na marasa lafiya a matakin kashi 2.

• A cikin marasa lafiya 3 da ke da PRs na dogon lokaci waɗanda aka sami biopsies na ciwon daji na gaba/baya, an faɗaɗa rubutun TCR na intratumoral kuma an rarraba jiyya tare da NOUS-209. An ƙara yawan ƙwaƙwalwar ƙwaƙwalwar T sakamako bayan jiyya.

A cikin ɗaya daga cikin waɗannan marasa lafiya uku, an gano takamaiman TCR neoantigen da aka haifar da alurar riga kafi daga abin da ke cikin ƙwayar ƙwayar cuta bayan jiyya na NOUS-209.

Sakamakon ya nuna cewa ƙwayoyin CD8+ T na neoantigen, wanda NOUS-209 ya jawo, suna faɗaɗa kuma suna bambanta kawai a kan jiyya tare da NOUS-209, kuma sun sami nasarar kutsawa cikin ƙananan ƙwayoyin tumo don yin aikin rigakafin ƙwayar cuta.

Marwan G. Fakih, MD, Kwararre kan Oncology na Likita a City of Hope's Duarte California, kuma mai binciken bincike ya ce: “Yayin da muka ga ci gaba a cikin zaɓuɓɓukan magani na MSI-High m ciwace-ciwacen daji a cikin 'yan shekarun nan, akwai sauran buƙatu masu mahimmanci da ba a cika su ba. Don haka yana da matuƙar ƙarfafawa don ganin waɗannan sabbin bayanan Fassara na Fassara na 1 waɗanda ke kwatanta yadda NOUS-209 ke haifar da haɓakar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta NOUS-1 ta NOUS-XNUMX ke haifar da ƙwaƙƙwaran ƙwayar sel T da TCR a cikin marasa lafiya da ke nuna amsoshi na asibiti. Ina matukar fatan samun cikakken bincike na sakamakon Mataki na XNUMX da ƙarin ci gaban asibiti. "

Dr. Elisa Scarselli, Babban Jami'in Kimiyya da Co-kafa Nouscom, ya ce: "Bayanan, da aka samu daga 12 metastatic MSI-H marasa lafiya, yana nuna alamar gama gari da aka lura bayan allurar rigakafi a cikin marasa lafiya tare da amsawar asibiti mai ɗorewa. Sa hannu yana da alaƙa da haɓakawa na TCR repertoire da rarrabuwa a cikin ƙari infiltrating lymphocytes ƙarfafa ta alurar riga kafi tare da NOUS-209, tare da a layi daya karuwa na T Kwayoyin tare da effector memory phenotype. Haka kuma, mun sami damar bin diddigin ƙwayoyin T da aka haifar da rigakafin a cikin waɗanda aka faɗaɗa jiyya a cikin ƙari na ɗaya daga cikin waɗannan marasa lafiya.

"Muna sa ran ginawa kan kwararar hujjojin ra'ayi ta hanyar yin amfani da mahimman koyo daga gwajin da ake yi don tallafawa ci gaban NOUS-209 a matsayin mai yuwuwar rigakafin cutar kansa ta farko ta neoantigen da ke fuskantar ciwace-ciwacen MSI-H."

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...